News | February 14, 2026
Akums surges in Q3 FY26 with 15% revenue jump, bags key EU & UK nods
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
ADQUEY’s approval opens the door to a new alternative for millions of Americans struggling with atopic dermatitis
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories
The surge has been driven largely by COCO stores, with 755 COCO and 165 FOFO outlets added this fiscal year
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Subscribe To Our Newsletter & Stay Updated
